 - Chemotherapysystemic therapy, radiotherapy, immunotherapy or surgery 21 days prior to registration or kinase inhibitor therapy 14 days prior to registration or failure to recover from toxicities to grade 1 or below from treatment; NOTE: concurrent therapy with octreotide is allowed providing that tumor progression on this therapy has been demonstrated; concurrent therapy with bisphosphonates e.g. zoledronic acid or denosumab is also allowed; NOTE: an unlimited number of prior chemotherapeutic or biologic therapies for malignant pheochromocytoma or paraganglioma is permitted; this includes prior anti-angiogenesis therapies such as tyrosine kinase inhibitors 